Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xiamen
Clinical trial register · China

Clinical Trials in Xiamen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xiamen University65 Merck Sharp & Dohme LLC36 Bristol-Myers Squibb11 BeOne Medicines10 AbbVie8
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Xiamen

391 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Chunshui He
Observational
600
Beijing, Xiamen, Hangzhou, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu
2027-01-01
Not yet open
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2026-11-16
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2026-11-11
Not yet open
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, Xi'an, Xiamen
2026-10-31
Not yet open
Xiamen Amoytop Biotech Co., Ltd.
Phase 1
24
Beijing, Shanghai, Ürümqi, Xiamen
2026-10-30
Recruiting
68Ga-XHER2 PET/CT for HER2 Assessment
NCT07885436Solid Tumor (Excluding CNS), HER2, PET / CT
The First Affiliated Hospital of Xiamen University
Not applicable
80
Xiamen
2026-10-22
Recruiting
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
NCT07885423Prostate Cancer (Diagnosis), ACP3, PET / CT
The First Affiliated Hospital of Xiamen University
Not applicable
25
Xiamen
2026-10-21
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
100
Xiamen
2026-10-20
Recruiting
Hoffmann-La Roche
Phase 3
325
Guangzhou, Mianyang, Changde, Huizhou, Ningbo, Sanmenxia, Shanghai, Xiamen
2026-10-16
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
292
Bozhou, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2026-10
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-26
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
300
Anqing, Hefei, Wuhu, Xuancheng, Beijing, Xiamen, Lanzhou, Guangzhou
2026-09-25
Recruiting
First Affiliated Hospital of Guangxi Medical University
Phase 3
352
Xiamen, Guangzhou, Baise City, Chongzuo, Guigang, Laibin, Liuzhou, Nanning
2026-09-24
Recruiting
InSilico Medicine Hong Kong Limited
Phase 3
320
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Haikou, Shijiazhuang
2026-09-09
Not yet open
Yefeng
Observational
60
Xiamen
2026-09-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
930
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-09
Not yet open
Zhongshan Sansure Hygene Biomedicine Co., Ltd.
Phase 3
240
Hefei, Beijing, Xiamen, Guangzhou, Tangshan, Wuhan, Changsha, Nanjing
2026-09
Recruiting
Neuboron Bio-SciTech Co., Ltd.
Phase 2
35
Xiamen
2026-08-31
Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
NCT07778212DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
DrugsPola-R-Chp·Orelabrutinib
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2026-08-30
Recruiting
Ocumension Therapeutics (Suzhou) Co., Ltd
Phase 3
842
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou
2026-08-25
Not yet open
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3
309
Bengbu, Wuhu, Fuzhou, Xiamen, Guangzhou, Shenzhen, Haikou, Baoding
2026-08-24
Recruiting
Pulnovo Medical, Inc.
Not applicable
750
Fuzhou, Xiamen, Nanjing, Jinan
2026-08-21
Not yet open
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
120
Xiamen
2026-08-01
Not yet open
Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion
NCT07754942Acute Ischemic Stroke, Large Vessel Occlusion
Zhongshan Hospital Xiamen University
Observational
50
Xiamen
2026-08-01
Not yet open
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis
NCT07587671Liver Cirrhosis, Portal Hypertension, Gastroesophageal Varices Bleeding, Esophageal Varices
West China Hospital
Not applicable
240
Chengdu, Chongqing, Xiamen
2026-08-01
Not yet open
Sun Yat-sen University
Phase 2
48
Xiamen, Guangzhou, Guilin
2026-08-01
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
240
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Changsha, Zhuzhou
2026-08
Not yet open
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Recruiting
Shanghai Henlius Biotech
Phase 1
48
Nanchang, Naning, Nanjing, Shanghai, Xiamen
2026-07-30
Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
NCT07749365DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
The First Affiliated Hospital of Xiamen University
Phase 2
53
Xiamen
2026-07-25
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
150
Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Guilin, Nanning
2026-07-15
Not yet open
Development and Validation of a Colorectal Cancer Diagnostic Model
NCT07692555Colorectal Cancer, Advanced Neoplasia, Prediction Models, Risk Stratification
Peking University Cancer Hospital & Institute
Observational
20,000
Beijing, Fuzhou, Xiamen, Yinchuan
2026-07-15
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
230
Fuzhou, Xiamen, Foshan, Guangzhou, Shenzhen, Zhongshan, Nanning, Dongguan
2026-07-01
Not yet open
Children's Hospital of Fudan University
Not applicable
200
Xiamen, Guangzhou, Zhengzhou, Jinan, Shanghai
2026-07-01
Not yet open
Zhongshan Hospital (Xiamen), Fudan University
Phase 2
15
Xiamen
2026-07-01
Recruiting
Zhiquan Hu
Phase 3
170
Hefei, Fuzhou, Xiamen, Guangzhou, Shenzhen, Enshi, Huanggang, Huangshi
2026-07-01
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
DrugAHB-171
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Hefei, Beijing, Xiamen, Guangzhou, Guilin, Nanning, Shijiazhuang, Wuhan
2026-06-18
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
36
Beijing, Henan, Shanghai, Sichuan, Xiamen, Zhejiang
2026-06-10
Recruiting
Shanghai Zhongshan Hospital
Not applicable
420
Chongqing, Fuzhou, Xiamen, Wuhan, Nanjing, Suzhou, Shanghai, Luzhou
2026-06-10
Recruiting
Xiamen Cardiovascular Hospital, Xiamen University
Early Phase 1
60
Xiamen
2026-06-06
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
320
Beijing, Chongqing, Xiamen, Guangzhou, Jiangmen, Meizhou, Qingyuan, Shenzhen
2026-06-05
Recruiting
Beijing Zhecheng Biotechnology Co., Ltd.
Not applicable
196
Xiamen
2026-06-04
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
Shanghai Henlius Biotech
Phase 1
258
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou
2026-05-25
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
160
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Recruiting
DLL3-Targeted PET/CT in Small Cell Lung Cancer
NCT07677787PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3
The First Affiliated Hospital of Xiamen University
Not applicable
20
Xiamen
2026-05-09
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Changsha, Changzhou, Guangzhou, Hangzhou, Huizhou, Suzhou, Wenzhou, Xiamen
2026-05-04
Recruiting
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
NCT07677774Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
The First Affiliated Hospital of Xiamen University
Not applicable
40
Xiamen
2026-05-01
Recruiting
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Recruiting
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
NCT06875063Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University
Phase 1
45
Xiamen
2026-04-30
Not yet open
Multi-Site Cortical Puncture for DOR
NCT07568639Diminished Ovarian Reserve (DOR)
First Affiliated Hospital of Guangxi Medical University
Not applicable
214
Xiamen, Guigang, Liuzhou, Nanning, Qinzhou
2026-04-30
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
NCT07547930Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
DrugTofacitinib
The First Affiliated Hospital of Xiamen University
Phase 2
8
Xiamen
2026-04-24
Recruiting
Ipsen
Observational
20
Beijing, Chongqing, Hunan, Nanjing, Shanghai, Xiamen
2026-04-16
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
752
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2026-04-15
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
40
Xiamen, Jinan, Chengdu
2026-04-13
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Not yet open
Decision Aid for Women Newly Diagnosed With Breast Cancer
NCT07497256Breast Cancer, Decision Aid, Shared Decision Making, Cost Effectiveness
Xiamen University
Not applicable
160
Xiamen
2026-04-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
24
Xiamen, Zhengzhou, Qingdao
2026-04
Not yet open
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2026-04
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
NCT07623382Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles
The First Affiliated Hospital of Xiamen University
Early Phase 1
20
Xiamen
2026-03-31
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
440
Anqing, Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2026-03-24
Recruiting
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
Simcere Pharmaceutical Co., Ltd
Phase 3
498
Xiamen, Changsha, Chengdu, Hangzhou
2026-03-11
Recruiting
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
NCT07458906DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
The First Affiliated Hospital of Xiamen University
Not applicable
80
Xiamen
2026-03-10
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
Recruiting
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC
NCT07451795Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Fudan University
Phase 2
66
Fujian, Shanghai, Xiamen
2026-03-02
Not yet open
Shanghai Escugen Biotechnology Co., Ltd
Phase 2
40
Beijing, Xiamen, Guilin, Langfang, Changde, Changsha, Zhuzhou, Xuzhou
2026-03-01
Not yet open
Xiamen Ophthalmology Center Affiliated to Xiamen University
Observational
2,000
Xiamen
2026-03-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Recruiting
Antengene Biologics Limited
Phase 1/2
132
Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Langfang, Shijiazhuang, Anyang
2026-02-27
Recruiting
Factors for Prolonged Hospital Stays in Patients Undergoing ERCP
NCT07568626Post-ERCP Adverse Events, ERCP Complications
Air Force Military Medical University, China
Observational
504
Xiamen, Xi'an
2026-02-15
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Observational
100
Xiamen, Tianjin
2026-02-15
Active, closed
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DrugRis-Rez
Hansoh BioMedical R&D Company
Phase 1
40
Beijing, Fuzhou, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-01-29
Not yet open
Kingdomway (Inner Mongolia) Nutritional Food Co., Ltd.
Not applicable
12
Xiamen
2026-01-28
Recruiting
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Shijiazhuang, Changchun, Wenzhou, Beijing, Chengdu, Chongqing
2026-01-21
Recruiting
Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT
NCT07720232Hypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced, Hyperlipidemia
Jianyin Zhou
Phase 4
180
Xiamen
2026-01-18
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
Not yet open
Left Ventricular Myocardial Work for Predicting Response to CRT
NCT07319065CRT Non-Response, LBBB, HF - Heart Failure, Healthy Adult
First Hospital of China Medical University
Observational
3,240
Hefei, Wannan, Fuzhou, Guizhou, Xiamen, Lanzhou, Jiangmen, Qinhuangdao
2026-01-01
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Recruiting
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
Tongji Hospital
Phase 2
77
Xiamen, Wuhan, Changchun, Taiyuan
2025-12-25
Recruiting
NucMito Pharmaceuticals Co. Ltd.
Phase 1
30
Xiamen, Guangzhou, Zhengzhou
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT06992739NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
The First Affiliated Hospital of Xiamen University
Phase 2
49
Xiamen
2025-12-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
Cascade Pharmaceuticals, Inc
Phase 3
135
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhanjiang, Nanning
2025-12-01
Not yet open
Xiamen Hospital of Traditional Chinese Medicine
Observational
4,000
Xiamen
2025-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
Eli Lilly and Company
Phase 2
400
Changsha, Hangzhou, Huzhou, Jinan, Shanghai, Shijiazhuang, Tianjin, Xiamen
2025-11-24
Recruiting
Beijing Tiantan Hospital
Not applicable
770
Beijing, Xiamen, Jiangmen, Shantou, Shenzhen, Liuzhou, Nanning, Wuzhou
2025-11-19
Recruiting
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy
DrugTS-1
West China Hospital
Phase 1/2
84
Xiamen, Chengdu
2025-11-18
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
By invitation
Xiamen Hospital of Traditional Chinese Medicine
Observational
130
Xiamen
2025-11-04
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
112
Xiamen
2025-11-01
Recruiting
Nudge-Based Shared Decision Making and Self-Management in Type 2 Diabetes: A Randomized Trial
NCT07129915Diabetes Mellitus, Type 2, Physician-Patient Relations, Self-management
Yunxuan Li
Not applicable
250
Xiamen
2025-11-01
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai
2025-10-08
Not yet open
Zhongshan Hospital Xiamen University
Observational
90
Xiamen
2025-10-01
Recruiting
Sanofi
Phase 3
980
Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi
2025-10-01
Not yet open
Xiamen Humanity Hospital
Not applicable
30
Xiamen
2025-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Active, closed
Cascade Pharmaceuticals, Inc
Phase 2
120
Fuzhou, Xiamen, Suzhou, Shanghai, Hangzhou, Wenzhou
2025-09-30
Recruiting
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Active, closed
Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT07107256Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugTQC2731
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
246
Fuyang, Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-09-25
Recruiting
Sanofi
Phase 4
218
Chengdu, Guangzhou, Hangzhou, Harbin, Ningbo, Xiamen
2025-09-22
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy, Immunotherapy, Chemotherapy
West China Hospital
Phase 1/2
88
Xiamen, Chengdu
2025-09-15
Not yet open
The Effect of Semaglutide on Bone Health
NCT07165158Osteoporosis, Osteoporosis Fracture, T2DM
DrugsMetformin·Semaglutide
The First Affiliated Hospital of Xiamen University
Phase 4
150
Xiamen
2025-09-15
Not yet open
Multicenter Validation Study on Autism Screening Using a Machine-assisted System
NCT07006948Autism Spectrum Disorder, Early Developmental Impairment, Language Development Disorders
Children's Hospital of Fudan University
Observational
1,000
Hefei, Xiamen, Liuzhou, Harbin, Kunshan, Xi'an, Shanghai, Chengdu
2025-09-15
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Hefei, Beijing, Fuzhou, Fyzhou, Xiamen, Lanzhou, Nanning, Harbin
2025-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
182
Beijing, Xiamen, Nanning, Nanchang, Jinan, Linyi, Hangzhou, Linhai
2025-09-09
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
68Ga-XACP3 PET/CT in Prostate Cancer
NCT07242014Prostate Cancer, PET/CT, ACP3
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2025-09-01
Not yet open
Huashan Hospital
Observational
28,800
Xiamen, Zhuhai, Zunyi, Xinxiang, Yichang, Nanjing, Jiujiang, Shenyang
2025-09-01
Recruiting
City University of Hong Kong
Not applicable
320
Xiamen, Guangzhou, Shenzhen, Chengdu
2025-09-01
Not yet open
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
NCT07126288Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD), Growth Hormone
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 2/3
268
Xiamen, Nanyang, Xinxiang, Wuhan, Suzhou, Nanchang, Pingxiang, Changchun
2025-08-31
Recruiting
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT07137052Nasopharyngeal Carcinoma (NPC), PET / CT
The First Affiliated Hospital of Xiamen University
Observational
732
Xiamen
2025-08-30
Recruiting
Ausper Biopharma Co., Ltd.
Observational
200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Not yet open
The First Affiliated Hospital of Xiamen University
Phase 2
34
Xiamen
2025-08-20
Active, closed
Ausper Biopharma Co., Ltd.
Phase 3
577
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-08-12
Recruiting
RemeGen Co., Ltd.
Phase 1/2
312
Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang
2025-08-11
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
NCT07085234Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
72
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen
2025-07-16
Recruiting
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou
2025-07-15
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
By invitation
Ultrasound Assessment of Fetal Growth Parameters
NCT07018362Fetal Clavicle Length, Fetal Scapular Width, Fetal Sternal Length, Fetal Scapular Length
The First Affiliated Hospital of Xiamen University
Observational
1,000
Xiamen
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
DrugNSAIDs
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
The First Affiliated Hospital of Xiamen University
Phase 2
43
Xiamen
2025-06-30
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai
2025-06-30
Active, closed
The First Affiliated Hospital of Xiamen University
Phase 1/2
79
Xiamen
2025-06-29
Active, closed
The First Affiliated Hospital of Xiamen University
Phase 1/2
95
Xiamen
2025-06-26
Recruiting
Hangzhou Converd Co., Ltd.
Not applicable
24
Xiamen
2025-06-23
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
75
Xiamen
2025-06-22
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
250
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou
2025-06-10
Active, closed
Mechanism and Application of Vitamin D in Idiopathic Sudden Sensorineural Hearing Loss
NCT07045883Idiopathic Sudden Sensorineural Hearing Loss
Zhongshan Hospital Xiamen University
Not applicable
197
Xiamen
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
DrugsIndomethacin·Diclofenac
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2025-05-22
Recruiting
Biogen
Phase 3
180
Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning
2025-05-22
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2025-05-09
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
113
Xiamen
2025-05-09
Recruiting
Biogen
Phase 3
454
Fuyang, Hefei, Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-05-08
Recruiting
CHina Adrenal Venous saMPling InvestigatiON
NCT07252284Hyperaldosteronism, Adrenal Venous Sampling, Adrenalectomy
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
5,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou
2025-05-01
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NCT07151898NSCLC, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2025-05-01
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Mirati Therapeutics Inc.
Phase 3
630
Bengbu, Hefei, Beijing, Chongqing, Fuzhou Fujian, Xiamen, Guangzhou, Shantou
2025-04-24
Not yet open
Xiamen Hospital of Traditional Chinese Medicine
Not applicable
30
Xiamen
2025-04-20
Recruiting
Shanghai Zhongshan Hospital
Phase 2
150
Xiamen, Shanghai, Wenzhou
2025-04-16
Recruiting
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
360
Xiamen
2025-04-03
Recruiting
Xiamen Cardiovascular Hospital, Xiamen University
Not applicable
112
Xiamen
2025-03-22
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
30
Xiamen
2025-03-15
Active, closed
Celgene
Phase 3
960
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Huizhou, Changzhou, Nanjing
2025-03-13
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Active, closed
Takeda
Phase 3
601
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
Suzhou Genhouse Bio Co., Ltd.
Phase 1
200
Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning, Guiyang, Zhengzhou
2025-03-07
Recruiting
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Bristol-Myers Squibb
Phase 3
530
Beijing, Chongqing, Fuzhou, Xiamen, Shantou, Harbin, Wuhan, Changsha
2025-02-25
Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
NCT06811844Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
The First Affiliated Hospital of Xiamen University
Phase 2
208
Xiamen, Zhangzhou, Haikou
2025-02-25
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Recruiting
Phase III Trial of VDJ001 In Patients With Idiopathic Multicentric Castleman Disease
NCT07872423Anti IL-6R, Castleman's Disease, Multicentric
Beijing VDJBio Co., LTD.
Phase 3
45
Beijing, Xiamen, Wuhan, Nanjing, Nanchang, Taiyuan, Chengdu, Hangzhou
2025-01-27
Not yet open
Fujian Cancer Hospital
Phase 2
34
Fuzhou, Xiamen
2025-01-25
Recruiting
BeOne Medicines
Phase 1
695
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
NCT07586787Proliferative Diabetic Retinopathy (PDR)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Not applicable
100
Beijing, Xiamen, Zhengzhou, Nanjing, Dalian
2025-01-01
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 1/2
86
Beijing, Xiamen, Guangzhou, Qingyuan, Shanghai, Chengdu
2024-12-30
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
142
Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi
2024-12-12
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
18
Xiamen
2024-12-12
Recruiting
68Ga-MY6349 PET/CT in Solid Tumors
NCT07046702Solid Tumor, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
300
Xiamen
2024-12-10
Recruiting
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
Pfizer
Phase 3
2,330
Chizhou, Beijing, Xiamen, Guangzhou, Nanning, Changsha, Nanchang, Changchun
2024-12-08
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Active, closed
Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
NCT06649721Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis
DrugsClofazimine·Delamanid·Bedaquiline·Levofloxacin
Huashan Hospital
Phase 3
120
Hefei, Beijing, Xiamen, Nanning, Liupanshui, Shijiazhuang, Harbin, Jiamusi
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
By invitation
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
NCT06688175Nasopharyngeal Neoplasms, Elderly, Chemotherapy
DrugIMRT
The First Affiliated Hospital of Xiamen University
Phase 2
32
Xiamen
2024-11-13
Active, closed
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Recruiting
A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment
NCT06757023Postoperative Complications, Postoperative Pain, Acupuncture
The First Affiliated Hospital of Xiamen University
Observational
110
Xiamen
2024-11-13
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Active, closed
Cola Ingestion for Esophageal Bolus Impaction
NCT06652620Esophageal Cancer
Fudan University
Not applicable
50
Xiamen, Anyang, Yangzhou, Jingdezhen, Shanghai
2024-11-01
Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
NCT07046689Breast Cancer, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2024-11-01
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
22
Xiamen
2024-10-21
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
NCT06696326Positron-Emission Tomography(PET), Prostate Cancer, Trophoblast Cell Surface Antigen 2
The First Affiliated Hospital of Xiamen University
Not applicable
100
Xiamen
2024-10-01
Recruiting
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Neoadjuvant Triple Therapy for Resectable HCC
NCT06569498Resectable Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
5
Xiamen
2024-09-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Recruiting
First Affiliated Hospital of Zhejiang University
Not applicable
99
Hefei, Fuzhou, Quanzhou, Xiamen, Zhangzhou, Shanghai, Hangzhou
2024-09-11
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
50
Xiamen
2024-09-01
Recruiting
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Active, closed
AbbVie
Phase 3
699
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Active, closed
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-08-07
Recruiting
Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome
NCT07691125Short Bowel Syndrome (SBS) in Adults
DrugRhGH
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 4
100
Xiamen, Nanjing
2024-07-31
Recruiting
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
36
Xiamen
2024-06-23
Active, closed
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
20
Xiamen
2024-06-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Recruiting
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
NCT06387056Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
DrugsPamiparib·Rezvilutamide·Tislelizumab·Docetaxel
The First Affiliated Hospital of Xiamen University
Phase 2
40
Xiamen
2024-04-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
39
Xiamen
2024-03-31
Recruiting
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Active, closed
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
12
Chongqing, Xiamen
2024-03-21
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
2,242
Chongqing, Xiamen, Wuwei, Qinzhou, Luoyang, Shangqiu, Xuchang, Wuhan
2024-03-11
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Recruiting
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
RemeGen Co., Ltd.
Phase 2/3
90
Beijing, Xiamen, Harbin, Zhengzhou, Wuhan, Changsha, Xuzhou, Jinan
2024-02-22
Active, closed
Genmab
Phase 3
1,095
Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou, Wuhan, Changsha
2024-02-05
By invitation
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1
96
Xiamen, Lanzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Wu’an
2024-02-04
Active, closed
DualityBio Inc.
Phase 3
228
Bengbu, Hefei, Beijing, Jilin City, Fuzhou, Xiamen, Guangzhou, Huizhou
2024-01-29
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Hefei, Beijing, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2024-01-23
Active, closed
DualityBio Inc.
Phase 3
541
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-01-18
Recruiting
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Shenyang
2024-01-11
Active, closed
AbbVie
Phase 4
120
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Wuhan, Qingdao, Chengdu
2024-01-09
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Recruiting
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
DrugsG-Chop·Lenalidomide
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06151106Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
DrugChidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
NCT06158399DLBCL - Diffuse Large B Cell Lymphoma, TP53
DrugsR-Chop·Azacitidine
The First Affiliated Hospital of Xiamen University
Phase 2
52
Xiamen
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugsLinperlisib·Chidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
90
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
25
Xiamen
2023-11-22
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
71
Xiamen
2023-11-15
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Recruiting
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Xiamen, Guangzhou, Zhengzhou, Wuhan, Yancheng, Shenyang, Qingdao, Shanghai
2023-10-23
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
342
Wuhu, Beijing, Xiamen, Guangzhou, Shenzhen, Guiyang, Haikou, Luoyang
2023-10-20
Recruiting
Shanghai Jiao Tong University School of Medicine
Phase 3
222
Fuzhou, Xiamen, Nanning, Nanjin, Suzhou, Shanghai, Kunming
2023-10-19
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
120
Lu'an, Beijing, Fuzhou, Xiamen, Wuwei, Shenzhen, Liuzhou, Yulin
2023-09-14
Active, closed
Bristol-Myers Squibb
Phase 3
774
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Changsha, Hohhot
2023-09-11
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
120
Xiamen
2023-09-01
Recruiting
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
1,312
Huainan, Beijing, Xiamen, Guangzhou, Shenzhen, Nanning, Shijiazhuang, Tangshan
2023-08-31
Recruiting
Peijia Medical Technology (Suzhou) Co., Ltd.
Not applicable
116
Beijing, Fuzhou, Xiamen, Guangzhou, Guangdong, Haerbin, Wuhan, Changsha
2023-08-01
Active, closed
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Active, closed
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2
155
Xiamen, Changsha
2023-07-19
Active, closed
OncoC4, Inc.
Phase 3
630
Hefei, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Nanning, Haikou
2023-06-28
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
100
Xiamen
2023-05-30
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
230
Hefei, Beijing, Xiamen, Xinxiang, Zhengzhou, Huai'an, Shanghai, Hangzhou
2023-05-16
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Active, closed
Shanghai Chest Hospital
Observational
305
Hefei, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Jinan, Shanghai
2023-05-08
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Active, closed
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2023-04-09
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Active, closed
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Active, closed
Xiamen Ophthalmology Center Affiliated to Xiamen University
Early Phase 1
11
Xiamen
2023-02-08
Active, closed
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Not yet open
Xiamen University
Observational
260
Xiamen
2022-12-15
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-12-01
Recruiting
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
Genmab
Phase 3
549
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2022-09-20
Active, closed
Sinotau Pharmaceutical Group
Phase 3
196
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Changchun
2022-08-31
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
DrugsErenumab·Eptinezumab
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
206
Fuzhou, Xiamen, Lanzhou, Guangzhou, Yulin, Zhengzhou, Changsha, Nanchang
2022-07-20
Active, closed
INSPIRIS China PMCF Study
NCT05404880Aortic Valve Replacement
Edwards Lifesciences
Observational
255
Beijing, Xiamen, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Xi'an, Chengdu
2022-07-13
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-07-01
Recruiting
Renal Nerve Denervation(RDN) and Renal Function
NCT05612906Effects of RDN on Renal Function
Zhengrong Huang
Observational
50
Xiamen
2022-06-01
Recruiting
Shanghai Zhongshan Hospital
Observational
6,000
Xiamen, Guangzhou, Zhengzhou, Wuhan, Jiangyin, Wuxi, Yangzhou, Yixing
2022-05-01
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
DrugsJAB-3312·Glecirasib
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Beijing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Wuhan, Changsha
2022-03-15
Active, closed
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
Recruiting
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Active, closed
China S3 PMS: SAPIEN 3 China Post Market Registry Study
NCT05168826Aortic Stenosis, Severe
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha, Shanghai, Xi’an
2022-01-24
Recruiting
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
NCT05305859Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2022-01-12
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Recruiting
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Active, closed
Akeso
Phase 3
296
Hefei, Fuzhou, Xiamen, Dongguan, Guangzhou, Jiangmen, Shantou, Shenzhen
2021-08-16
Active, closed
Guangdong Provincial People's Hospital
Phase 3
440
Xiamen, Guangzhou, Huizhou, Jiangmen, Shenzhen, Zhanjiang, Nanning, Shangqiu
2021-08-12
Recruiting
The Brain Mechanism of Social Emotion and Communication in Infants Aged 0 to 6 Years
NCT05040542Brain Development, Behavior Disorders, Child, Intellectual Developmental Disorders
Children's Hospital of Fudan University
Observational
3,001
Xiamen
2021-08-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Hefei, Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Nanning, Zhengzhou
2021-06-18
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Active, closed
Daiichi Sankyo
Phase 3
490
Heifi, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Changshan
2021-05-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,688
Bengbu, Beijing, Chongging, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou
2021-04-14
Recruiting
HANGZHOU Solution in Bicuspid AS Undergoing TAVR
NCT04722796Aortic Stenosis, Aortic Stenosis With Bicuspid Valve
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
508
Bengbu, Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2021-04-12
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Active, closed
Bayer
Phase 3
774
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Active, closed
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Active, closed
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
320
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guangxi, Haikou
2020-08-13
Active, closed
Hoffmann-La Roche
Phase 1/2
237
Changchun, Chengdu, Shanghai, Tianjing, Xiamen
2020-08-12
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
648
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2020-08-11
Active, closed
AstraZeneca
Phase 3
134
Chengdu, Shanghai, Tianjin, Xiamen, Zhengzhou
2020-07-20
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-07-06
Active, closed
Eli Lilly and Company
Phase 3
996
Hefei, Chongqing, Xiamen, Foshan, Guangzhou, Wuhan, Changsha, Changzhou
2020-06-22
Active, closed
Epizyme, Inc.
Phase 3
599
Fuzhou, Xiamen, Guiyang, Zhejiang, Shijiazhuang, Zhengzhou, Changsha, Changchun
2020-06-11
Active, closed
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Active, closed
Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial)
NCT03802253Impaired Glucose Regulation, Overweight/Obese, Time-restricted Eating
The First Affiliated Hospital of Xiamen University
Not applicable
142
Xiamen
2020-05-04
Recruiting
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
NCT06530004Nephrotic Syndrome, Rituximab, Children, Efficacy
DrugRituximab
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2020-03-01
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2020-02-28
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Recruiting
Comparison of FDG and FAPI in Patients With Various Types of Cancer
NCT04416165Tumor, Solid, Positron-Emission Tomography, Metastasis
The First Affiliated Hospital of Xiamen University
Not applicable
3,000
Xiamen
2019-10-20
Active, closed
Hoffmann-La Roche
Phase 1/2
498
Beijing, Jinan, Shanghai, Xiamen
2019-08-13
Active, closed
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
10,000
Xiamen
2019-03-20
Recruiting
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
NCT03087032Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
DrugsInsulin glargine·Liraglutide
The First Affiliated Hospital of Xiamen University
Phase 4
164
Xiamen
2019-01-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan
2018-12-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guanghzou, Guangzhou, Guiyang
2018-08-21
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Haerbin, Nanjing, Hangzhou, Beijing, Hefei, Xiamen, Zhengzhou
2018-06-21
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
AbbVie
Phase 3
747
Beijing, Xiamen, Guangzhou, Wuhan, Changsha, Nanjing, Nanchang, Changchun
2018-03-21
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
140
Xiamen
2018-02-15
Active, closed
Pfizer
Phase 3
1,054
Hefei, Beijing, Fuzhou, Xiamen, Wuhan, Lianyungang, Nanjing, Nantong
2017-12-18
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
DrugVedolizumab
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Beijing, Daping, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Shatin
2017-03-07
Recruiting
Registry of Multicenter Brain-Heart Comorbidity in China
NCT05961748Ischemic Heart Disease, Cardiac Arrest, Atrial Fibrillation, Heart Failure
Beijing Tiantan Hospital
Observational
100,000
Beijing, Fuzhou, Xiamen, Shenzhen, Harbin, Zhengzhou, Shanghai, Shanxi
2012-01-01
Rows per page Showing 1–391 of 391
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/xiamen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 391 of those studies with a site in Xiamen.

How many clinical trials are recruiting in Xiamen?

245 of the 391 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 45 have not yet opened recruitment, 97 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xiamen), 391 studies
PhaseStudiesRecruitingShare
Phase 31376335%
Phase 2655116.6%
Observational523213.3%
Not applicable493712.5%
Phase 1/238269.7%
Phase 128207.2%
Phase 41072.6%
Phase 2/3972.3%
Early Phase 1320.8%

Most active sponsors

Lead sponsors with the most studies (Xiamen)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xiamen University6556
Merck Sharp & Dohme LLC3618
Bristol-Myers Squibb116
BeOne Medicines107
AbbVie81
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.62
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.64
Ausper Biopharma Co., Ltd.54
Beijing InnoCare Pharma Tech Co., Ltd.53
RemeGen Co., Ltd.54
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.